-       Report 
- November 2022
-  125 Pages 
- Global 
   From       €2227EUR$2,490USD£1,959GBP 
          -       Report 
- January 2023
-  343 Pages 
- Global 
   From       €4472EUR$5,000USD£3,934GBP 
          -       Report 
- March 2024
-  200 Pages 
- Global 
   From       €3712EUR$4,150USD£3,265GBP 
          -       Report 
- January 2024
-  200 Pages 
- Global 
   From       €3712EUR$4,150USD£3,265GBP 
            -       Report 
- July 2024
-  100 Pages 
- Global 
   From       €2683EUR$3,000USD£2,360GBP 
      €3354EUR$3,750USD£2,950GBP 
             -       Report 
- April 2024
-  30 Pages 
- Global 
   From       €2326EUR$2,600USD£2,046GBP 
      €2907EUR$3,250USD£2,557GBP 
          -       Report 
- April 2023
-  120 Pages 
- Global 
   From       €4249EUR$4,750USD£3,737GBP 
          -       Report 
- August 2025
-  82 Pages 
- India 
   From       €3131EUR$3,500USD£2,754GBP 
          -       Report 
- October 2023
-  128 Pages 
- North America 
   From       €3578EUR$4,000USD£3,147GBP 
          -       Report 
- August 2023
-  114 Pages 
- Global 
   From       €4025EUR$4,500USD£3,541GBP 
          -       Report 
- December 2023
-  265 Pages 
- Global 
   From       €3220EUR$3,600USD£2,832GBP 
            -       Report 
- January 2024
-  150 Pages 
- Global 
   From       €3444EUR$3,850USD£3,029GBP 
      €4338EUR$4,850USD£3,816GBP 
          -       Report 
- June 2025
-  250 Pages 
- India 
   From       €2495EUR$2,789USD£2,194GBP 
          -       Report 
- June 2025
-  250 Pages 
- Saudi Arabia 
   From       €2495EUR$2,789USD£2,194GBP 
          -       Report 
- June 2025
-  250 Pages 
- Mexico 
   From       €2495EUR$2,789USD£2,194GBP 
          -       Report 
- June 2025
-  250 Pages 
- Vietnam 
   From       €2495EUR$2,789USD£2,194GBP 
          -       Report 
- June 2025
-  250 Pages 
- Brazil 
   From       €2495EUR$2,789USD£2,194GBP 
          -       Report 
- June 2025
-  250 Pages 
- Japan 
   From       €2495EUR$2,789USD£2,194GBP 
          -       Report 
- August 2024
-  200 Pages 
- Global 
   From       €3461EUR$3,869USD£3,044GBP 
          -       Report 
- December 2023
-  76 Pages 
- Global 
   From       €890EUR$995USD£783GBP 
       
      In the landscape of vaccines, mRNA (messenger RNA) vaccines represent a novel technology that has garnered substantial attention for its role in rapid vaccine development. These vaccines operate by instructing cells to produce a protein that triggers an immune response without using a live virus. This innovative approach stands out for its ability to be developed and scaled up swiftly in response to infectious diseases, offering a flexible platform for vaccine creation. While traditional vaccine    development may take years of research and testing, mRNA vaccines can be designed once the genetic information of a pathogen is known.
The adoption of mRNA vaccines has been driven by their potential to address a broad spectrum of diseases beyond just infectious agents. Research is being conducted into their applicability in treating and preventing cancers, genetic disorders, and autoimmune diseases. This expansion of mRNA technology into various medical domains has contributed to the diversification of the vaccine industry.
Several prominent companies are active in the mRNA vaccines market, shaping its trajectory with their research and development efforts. Notable firms include Moderna, Pfizer in collaboration with BioNTech, and CureVac. These companies have invested heavily in mRNA technology, leading to advances that have solidified their positions as key players in the pharmaceutical and biotechnology sectors. Show Less   Read more